Project 1: Jacobio Phase I/II Clinical Data of KRAS G12C Inhibitor Glecirasib (JAB-21822) Monotherapy and Combination Treatment for Advanced Solid Tumors
石远凯 中国医学科学院北京协和医学院长聘教授、中国癌症基金会理事长
SHI Yuankai , Professor in Tenure, Chinese Academy of Medical Sciences & Peking Union Medical College; Chairman of Cancer Foundation of China
14:20 - 14:40
中天（上海）生物科技有限公司
Microbio (Shanghai) Co., Ltd.
项目2：全球首创广效抗新冠药物MBS-COV（SNS812）简介及一期临床结果首发
Project 2: Introduction to the World's First Broad-Spectrum Anti-SARS-CoV-2 Drug, MBS-COV（SNS812）, and the First Release of Phase I Clinical Trial Results
張翼中 中天（上海）生物科技有限公司总经理
Owen Chang , General Manager, Microbio (Shanghai) Co., Ltd.
Shun-Cheng Chang , Director, Division of Plastic Surgery, Department of Surgery, Taipei Medical University-Shuang Ho Hospital, Taiwan; Executive Supervisor, Taiwan Surgical Association; Director, Taiwan Society For Wound Care; Assistant professor, Department of Surgery, Taipei Medical University
16:20 - 16:40
广州再极医药科技有限公司
Guangzhou Maxinovel Pharmaceuticals Co., Ltd.
项目8：MAX-40279：FLT3野生型AML治疗的新突破
Project 8: MAX-40279 as the Novel Treatment of FLT3 Wildtype Acute Myeloid Leukemia
冯振华 再极医药科技有限公司科学与运营副总裁
FENG Zhenhua , Vice President of Science and Operations, Maxinovel Pharma.
16:40 - 17:00
明济生物制药(北京)有限公司
FutureGen Biopharmaceutical(Beijing) Co., Ltd.
项目9：靶向CLDN18.2 ADCC增强型单抗FG-M108应用于晚期胃癌的临床Ⅰ/Ⅱ期试验
Project 9:The Phase Ⅰ/Ⅱ Clinical Study of Monoclonal Antibody FG-M108 Targeting CLDN18.2 with Enhanced ADCC Activity for Advanced Gastric Cancer
靳照宇 明济生物制药（北京）有限公司董事长&CEO
JIN Zhaoyu , Chaiman&CEO of FutureGen Biopharmaceutical (Beijing) Co., Ltd.
会务组联系人